A phase II study of bisantrene in patients with relapsed/refractory acute myeloid leukemia.
Jonathan CanaaniIvetta DanyleskoNoga ShemtovMaya ZlotnickKira LozinskyOhad BenjaminiRonit YerushalmiMeital NagarChen DorAvichai ShimoniAbraham AvigdorArnon NaglerPublished in: European journal of haematology (2020)
In view of the observed low toxicity, a follow-up study combining bisantrene with complementary anti-leukemic therapy is planned.
Keyphrases
- acute myeloid leukemia
- phase ii study
- open label
- locally advanced
- allogeneic hematopoietic stem cell transplantation
- oxidative stress
- placebo controlled
- rectal cancer
- clinical trial
- squamous cell carcinoma
- radiation therapy
- stem cells
- randomized controlled trial
- multiple myeloma
- mesenchymal stem cells
- study protocol
- double blind